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Background: The diagnosis of leptomeningeal metastasis (LM) in patients with solid tumors remains difficult.
The usual diagnostic methods of cytomorphological assessment of cerebro-spinal fluid (CSF) and gadolinium
enhanced MRI of the entire neuraxis lack both specificity and sensitivity. The Veridex CellSearchW technology has
been designed for the detection of circulating tumor cells (CTC) in blood from cancer patients and validated for
the follow-up and prognosis of breast, prostate, colorectal, and lung cancer. Our aim was to adapt this technology
for the detection and the enumeration of tumor cells in the CSF of breast cancer patients presenting with LM.
Methods: On the occasion of a randomized phase III study evaluating the role of the intrathecal treatment in LM
from breast cancer (DEPOSEIN, EudraCT N°: 2010-023134-23), the CellSearchW technology was adapted to direct
enrichment, enumeration and visualization of tumor cells in 5 mL CSF samples, collected on CellSaveW Preservative
Tubes and analyzed within 3 days after CSF sampling.
Results: Sixteen CSF of 8 patients with primary breast cancer presenting with LM were studied. EpCAM+/cytokeratin +
cells with typical morphology could be observed and enumerated sequentially with reproducible results in low or
elevated numbers in 8 patients.
Conclusion: This methodology, established on a limited volume of sample and allowing delayed processing,
could prove of great interest in the diagnosis and follow-up of cancer patients with LM, especially to appreciate
the efficacy of chemotherapy.
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Solid tumors, mostly breast cancer, lung cancer and me-
lanoma, can result in leptomeningeal metastasis (LM) in
5 to 19% of patients [1]. The incidence of central ner-
vous system (CNS) metastasis and LM may increase in
the coming years because of a prolonged control of
extra-cerebral disease and because of the use of antineo-
plastic agents with a poor diffusion into the CNS [2].* Correspondence: E-lerhun@o-lambret.fr
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reproduction in any medium, provided the orThe median survival of untreated patients with LM is
4–6 weeks. Breast cancers LM have the best prognosis,
and median overall survival may reach 3 to 5 months
with a combined treatment in recent studies [3-8].
The aim of treatment is to improve or stabilize neuro-
logical functions, maintain quality of life and prolong
survival [1].
Prognostic factors have been identified: age, perform-
ance status, neurological status, LM characteristics, cere-
brospinal fluid (CSF) block, LM related encephalopathy,
extension of systemic disease and its treatment options,
interval between diagnosis of primary tumour and LMl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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heterogeneous among studies and are not very well
validated. LM should be diagnosed in the early stages
of the disease to prevent the progression of disabling
neurological deficits. The diagnosis is assessed by CSF
cytomorphological analysis or by concomitant typical
CNS involvement symptoms and gadolinium enhanced
magnetic resonance imaging (MRI) signs. CNS signs
and symptoms, indicative of LM in more than 90%
of patients, may be pleomorphic and are often subtle
and difficult to distinguish from other cancer or anti-
neoplastic treatment complications [10]. The specificity
of gadolinium-enhanced MRI signs is up to 100% in
solid tumors, balanced by a risk of false negative as
high as 65% and false positive approaching 10% [11].
Evidence of malignant cells in the CSF is diagnostic
of LM. However, in patients ultimately positive for
CSF cytology, up to 45% are cytologically negative on
initial examination. The sensitivity reaches 80% with
a second CSF analysis, but little benefit is obtained
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of symptoms and delayed processing have been reported
to be sources of error [10-13]. Various biomarkers, such
as tumour antigens, molecules involved in extravasation,
migration or angiogenesis as well as chemokines [14-18]
are under evaluation for their performance in detecting
LM. Flow cytometry has been proposed as well as
cytomics approaches, especially for CNS haematological
involvement [17,19].
CSF cytomorphology thus remains the gold stand-
ard for LM detection, but readout is only qualitative
and not quantitative. Besides microscopic enumeration
and morphological examination, cellular biomarkers
appear promising.
The Veridex CellSearchW technology has been
designed for the detection of circulating tumour cells
(CTC) in blood from cancer patients and validated for
the follow-up and prognosis of breast, prostate, colorec-
tal, and lung cancer [20-22]. We adapted the technique
and applied it to detect malignant cells in the CSF of 8
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Table 2 CSF characteristics at the time of the CellSearchW technology analysis
Inclusion number,
date of CSF sampling
Treatment received for LM
at the time of CSF sampling
for CVT





03 - 01 IV paclitaxel for 2 months then Proteinorachia: 0.22 g/L No malignant cell (10 mL) 0 CSFTC per mL
carboplatin Glycorachia: 3.5 mmol/L
No IT chemotherapy Chlorurorachia: 121 mol/L
05 - 01 IV paclitaxel since LM diagnosis Proteinorachia: 1.13 g/L Presence of malignant cells
(10 mL)
626 CSFTC per mL
No IT chemotherapy Glycorachia: 2.4 mmol/L
Chlorurorachia: 121 mol/L
05 - 02 IV paclitaxel since LM diagnosis Proteinorachia: 1.42 g/L Presence of malignant cells
(10 mL)
1600 CSFTC per mL
No IT chemotherapy Glycorachia: 1.8 mmol/L
Chlorurorachia: 117 mol/L
05 - 03 IV paclitaxel since LM diagnosis Proteinorachia: 2.90 g/L No malignant cell (10 mL) 2100 CSFTC per mL
No IT chemotherapy Glycorachia: 0.3 mmol/L
Chlorurorachia: 118 mol/L
06 - 01 None Proteinorachia: 0.51 g/L Presence of malignant cells
(3 mL)
7 CSFTC per mL
Glycorachia: 3.7 mmol/L
Chlorurorachia: 126 mol/L
09 - 01 None Proteinorachia: 1.90 g/L Presence of malignant cells
(6 mL)
208 CSFTC per mL
Glycorachia: 3.3 mmol/L
Chlorurorachia: 110 mol/L
09 - 02 Oral vinorelbine Proteinorachia: 1.64 g/L Not interpretable (10 mL) 130 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 4.9 mmol/L
Chlorurorachia: 108 mol/L
09 -03 Oral navelbine Proteinorachia: NA Presence of malignant cells
(10 mL)
75 CSFTC per mL
IT liposomal cytarabine (X2) Glycorachia: NA
Chlorurorachia: NA
09 -04 Oral navelbine Proteinorachia: 1.88 g/L Presence of malignant cells
(10 mL)
82 CSFTC per mL
IT liposomal cytarabine (X3) Glycorachia: 4.5 mmol/L
Chlorurorachia: 116 mol/L
10 - 01 None Proteinorachia: 0.80 g/L Presence of malignant cells
(5 mL)
0.2 CTC per mL
Glycorachia: 3.4 mmol/L
Chlorurorachia: 121 mol/L
10 - 02 FEC 50 Proteinorachia: 0.90 g/L Presence of malignant cells
(6 mL)
0.4 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 3.2 mmol/L
Chlorurorachia: 120 mol/L
11 - 01 None Proteinorachia: 7.08 g/L Presence of malignant cells
(6 mL)
478 CSFTC per mL
Glycorachia: 2 mmol/L
Chlorurorachia: 113 mol/L
11 - 02 Capecitabine Proteinorachia: 9.04 g/L Presence of malignant cells
(8 mL)
940 CSFTC per mL
No IT chemotherapy Glycorachia: 3.2 mmol/L
Chlorurorachia: 100 mol/L
12 - 01 None Proteinorachia: 0.39 g/L Presence of malignant cells
(10 mL)
5 CSFTC per mL
Glycorachia: 5.4 mmol/L
Chlorurorachia: 119 mol/L
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Table 2 CSF characteristics at the time of the CellSearchW technology analysis (Continued)
12 - 02 Oral capecitabine + lapatinib Proteinorachia: 0.21 g/L No malignant cells (8 mL) 0 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 5.4 mmol/L
Chlorurorachia: 119 mol/L
13 - 01 None Proteinorachia: 8.84 g/L Presence of malignant cells
(7 mL)
1560 CSFTC per mL
Glycorachia: 2.4 mmol/L
Chlorurorachia: 106 mol/L
LM Leptomeningeal Metastasis, CSF CerebroSpinal Fluid, CSFTC CSF Tumor Cells, IT IntraThecal, IV IntraVenous, FEC Fluorouracil Epirubicin Cyclophosphamide, CVT
CellSearchW Veridex Technology, NA Not Available.
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All the patients were included into a randomized phase
3 study evaluating the role of the intrathecal treatment
in LM from breast cancer (DEPOSEIN, EudraCT N°:
2010-023134-23) after approbation of the appropriate
regional ethic committee (“Comité de Protection des
Personnes - CPP Nord Ouest III) on May 3rd 2011 and
in compliance with the Helsinki Declaration. All patients
had given their written informed consent for the transla-
tional study. DEPOSEIN is a multicentric randomized
phase III study designed to assess the role of intra-CSF
liposomal cytarabine in the treatment of LM. Patients
are randomized in 2 arms: liposomal cytarabine intra-
CSF and concomitant systemic treatment versus sys-
temic treatment alone. LM diagnosis was established in
8 patients with primary breast cancer, according to usual
diagnostic criteria. The CellSearchW technology defines
CTCs after immunomagnetic enrichment of cells expres-
sing EpCAM, using nuclear staining with 4’, 6-diamidino-
2- phenylindole (DAPI), and immunofluorescence de-
tection of cytokeratin and CD45 [22]. Five mL of CSF
samples were collected on CellSaveW Preservative Tubes
(Veridex, Raritan, NJ) and analyzed within 3 days after
CSF sampling using the standard CellSearchW protocol
and the CTC Epithelial Cell Kit (Veridex, Raritan, NJ).
The methodology is designed to initially eliminate, in
centrifuged blood samples, the plasma above the buffy
coat and erythrocytes by optically detecting the level of
the latter. In order to avoid undue alarms, after depo-
sition of 5 mL of CSF in the conic tube of the “circula-
ting tumor cell kit”; the outside of the tube was simply
darkened with a black felt-tip up to the fluid level to
mimick the erythrocytes level. Five mL of dilution buffer
were then added and the mixture homogeneized and
centrifuged. The “lured-tube” was then placed into the
preparation station and submitted to automate prepa-
ration as for blood samples.
Briefly, the latter resulted in an enriched sample where
cells were optically aligned along the upper panel of a
glass chamber, maintained by strong magnets, allowing
for automated fluorescence microscopy and cell images
digitalization, a cell being defined as both nuclear DAPI
and cell-surface staining. This allowed the observationof EpCAM+/cytokeratin + cells with a DAPI-stained
nucleus and no CD45 staining, magnetically maintained
in a single plane for electronic image analysis and
digitalization. The automated fluorescence microscope
proposes galleries of cells, which were validated upon vi-
sual image review. DAPI+/CD45+/EpCAM-/cytokeratin-
cells were counted as leukocytes.
In parallel, cytocentrifuge smears of each CSF sample
were prepared within one hour after CSF sampling and
stained (May Grunwald Giemsa) for visual cytomorpho-
logical examination of tumor cells, and standard CSF
biochemical composition was analyzed.Results
The characteristics of the patients at the time of LM
diagnosis are described in Table 1. Five patients had con-
comitant parenchymal brain metastasis. At LM diagno-
sis, 6 patients presented with symptoms and signs,
mostly including cauda equina syndrome and dizziness.
Proteinorachia varied from 0.24 to 7.08 g/L. CSF sam-
ples volumes varied between 5 and 10 mL for usual
cytomorphological analysis, tumor cells were detected
but not enumerated in all the patients and MRI showed
evidence of LM signs in 8 patients.
The first part of the translational study was to adapt
the CellSearchW technology for the detection and enu-
meration of tumor cells in the CSF of breast cancer LM.
Sixteen CSF samples were available for the evaluation
of the innovative method: These samples are described
in Table 2. All CSF samples were obtained at lumbar
site and analysed at LM diagnosis or at different times
during LM treatment. Malignant cells were observed
at cytomorphological analysis in 12 samples, and in
14 samples with the CellSearchW technology, with
tumor cells numbers ranging between 1 and 10500 /5 mL.
Figure 1 shows representative epithelial tumour cells
detected in CSF from one breast cancer patient
by CellSearchW technology. These cells have similar
aspects to epithelial tumour cells described in blood
as CTC from breast cancer patients [17]. Figure 2
summarizes quantitative results of tumor cells in CSF by
CellSearchW technology.
Figure 1 Collection of validated images of tumor cells (EpCAM+/
cytokeratin + cells with a DAPI-stained nucleus and no CD45
staining) detected in the CSF from a patient with LM secondary
to breast cancer.
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one sample from patient 09 because of deterioration of
the cells, despite an usual procedure of sampling and pro-
cessing of the CSF, while CellSearchW showed 650 tumor
cells in 5 mL. In another patient, the usual cytologic ana-
lysis did not detect any tumor cell but CellSearchW tech-
nology enumerated more than 2000 cells /mL.
Three patients were studied once with both techni-
ques, with concordant positive and negative results. Two
patients were studied twice, one with low levels of cells
(1 and 2 cells /5 mL) and the other with elevated num-
bers (2392 and 4700 cells /5 mL). One patient was ana-
lyzed three times with numbers increasing from 3129 to
10500 cells /5 mL. Another patient was studied fourFigure 2 Individual numbers of tumor cells in CSF detected using the
study (identified by their number of inclusion at the right box).times, with numbers of tumor cells decreasing from
1042 cells to 408 cells /5 mL).
Discussion
In cancer patients, the diagnosis of LM remains a major
problem. CNS signs and symptoms orienting towards a
diagnosis of LM are often subtle. Diagnosis assessment
implies the use of specific techniques, which are not ap-
plied in the usual follow-up of solid tumour patients,
namely gadolinium enhanced MRI and CSF cytomor-
phological analyses. Yet, even the latter may be not con-
tributive, as many patients are both radiographically and
cytomorphologically negative even in the presence of
evocative symptoms.
Different biomarkers have been tested in order to
increase the sensitivity of CSF analyses but their use is
hampered by a poor specificity/sensitivity, a lack of
standardization of CSF sampling and processing, and the
absence of agreement on cut-off levels. Because of all
these limitations, CSF cytomorphology remains the gold
standard for CSF analysis.
The CellSearchW method provides a semi-automated
cell analysis, based on the assessment of nuclear and
surface markers, which vastly improves the sensitivity,
reliability, objectivity, and accuracy of circulating tumor
cells detection in the blood compared to cytomorpho-
logy [20-22]. In recent studies [23,24], CellSearchW tech-
nology, applied by spiking blood with CSF [24], was
shown to be of interest for the early detection of CSF
malignant cells. We present here a simple modification
of this technology allowing for a precise direct quantifi-
cation of CTC in only 5 mL of CSF. Moreover, the use
of CellSaveW Preservative tubes for collection authorizedCellSearchW technology from the 8 patients included in the
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esting for centralized analyses. The specificity of this
technique, besides the use of tumor-associated markers,
is enhanced by visual appreciation of the digitalized cells.
Indeed, no cells with a tumor-like morphology or pheno-
type were detected in the CSF of a small series of control
patients without LM (data not shown). The presence
of an additional free channel for other reagents also
makes possible to analyse the cell’s HER2-Neu or EGFR
immunofluorescence or to investigate for any other rele-
vant marker allowing the exploration of these neuro-
logical metastatic cells.
Furthermore, sequential studies in our short series ap-
pear very concordant with either low or elevated levels
of cells, which is very encouraging for the evaluation
of therapies.
Conclusions
We report in this pilot study an easy new method for
the identification and the quantification of malignant
cells in the cerebrospinal fluid. These results, which
need to be confirmed in a larger series, suggests that
CellSearchW technology could be of interest during can-
cer patients’ follow-up, for initial characterization of LM
and notably to evaluate the efficacy of chemotherapy in
its management. According to these first results, the
CellSearchW technology will continue to be evaluated
during the clinical randomized study DEPOSEIN.
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